Survival Impact of Internal Mammary or Supraclavicular Lymphadenectomy

Completed

• Conditions: Ovarian Cancer Stage IV; Lymph Node Metastases

• Registration Number: NCT05005650
• Lead Sponsor: Seoul National University Hospital

Brief Summary

To evaluate the survival impact of extensive lymphadenectomy as part of debulking surgery in stage IVB ovarian cancer with supradiaphragmatic lymph node metastasis.

Detailed Description

Not available

Study Timeline

• Study Start: 2021-06-01
• Study First Submitted: 2021-08-06
• Study First Submitted QC: 2021-08-10
• Study First Posted: 2021-08-13
• Primary Completion: 2021-08-31
• Study Completion: 2021-12-31
• Status Verified: 2023-06
• Last Update Submitted: 2023-06-23
• Last Update Posted: 2023-06-26

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Female
• Target Recruitment: 121

Inclusion Criteria

• Histologically diagnosed ovarian, fallopian tubal, primary peritoneal cancer
• Patients suspected of metastatic lymph nodes in the cardiophrenic, internal mammary, and/or supraclavicular lymph node by CT (size larger than 5mm)
• Patients clinically diagnosed FIGO stage IVB ovarian, fallopian tubal, primary peritoneal cancer
• Patients underwent debulking surgery (primary debulking surgery or interval debulking surgery) at Seoul National University Hospital from January 2010 to January 2020
• Patients age 18-90

Exclusion Criteria

• Borderline or benign ovarian disease
• Patient didn't undergo debulking surgery
• Non-epithelial ovarian cancer

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Progression-free survival	From date of treatment until the date of first documented progression or date of death (by any cause, in the absence of disease progression) whichever came first, assessed up to 120 months	the time interval from the treatment start date to disease recurrence or progression date

Secondary Outcome Measures

Name	Time	Method
Overall survival	From the date of treatment start date until death due to any cause, assessed up to 120 months	the time interval from the treatment start date to death or end of study date

Trial Locations

Locations (1)

Seoul National University Hospital; 🇰🇷 Seoul, 시/도/주, Korea, Republic of